Skip to main content
Top
Published in: Pituitary 2/2011

01-06-2011

Analysis of thrombophilic genetic mutations in patients with Sheehan`s syndrome: is thrombophilia responsible for the pathogenesis of Sheehan`s syndrome?

Authors: Deniz Gokalp, Alpaslan Tuzcu, Mithat Bahceci, Orhan Ayyildiz, Murat Yurt, Yusuf Celik, Gulistan Alpagat

Published in: Pituitary | Issue 2/2011

Login to get access

Abstract

The gene mutations of Factor V R506Q (FV-Leiden), prothrombin (FII G20210A), methylene tetrahydrofolate reductase (MTHFR) C677T and A1298C and PAI-1 4G/5G are well-established risk factors for thrombosis. We aimed to investigate the prevalence of these gene mutations and their possible impact on the development of pathogenesis in patients with Sheehan’s syndrome (SS). 40 female patients with SS compared to a control group of 45 healthy women. The presence of FV-Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G gene mutations were assessed by polymerase chain reaction analysis with a light cycler analyzer. An odds ratio of greater than one is considered to increase the risk of SS disease as found in Factor V Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G polymorphism, as follows respectively: 1.13, 1.85, 6.00, 8.14 and 1.45. MTHFR C677T and MTHFR A1298C polymorphism were found significantly higher in SS patients than the control group (P < 0.001), however FV-Leiden, FII G20210A and PAI-1 4G/5G polymorphism showed no significant difference (P > 0.05). The level of plasma total homocysteine (tHcy) was significantly higher in patients with SS than in the control group (P < 0.001). We suggest that the genetic mutations of FV-Leiden, FII G20210A, MTHFR C677T, MTHFR A1298C and PAI-1 4G/5G increase the risk of SS. Also, high plasma tHcy levels may be a risk factor for the development of SS.
Literature
1.
go back to reference Sheithauer B, Sano T, Kovacs K, Young W Jr, Ryan N, Randall R (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 patients. Mayo Clin Proc 65(4):461CrossRef Sheithauer B, Sano T, Kovacs K, Young W Jr, Ryan N, Randall R (1990) The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 patients. Mayo Clin Proc 65(4):461CrossRef
2.
go back to reference Goswami R, Kochupillai N, Crock P, Jaleel A, Gupta N (2002) Pituitary autoimmunity in patients with Sheehans syndrome. J Clin Endocr Metab 87(9):4137CrossRefPubMed Goswami R, Kochupillai N, Crock P, Jaleel A, Gupta N (2002) Pituitary autoimmunity in patients with Sheehans syndrome. J Clin Endocr Metab 87(9):4137CrossRefPubMed
4.
go back to reference Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A (2002) Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 17:1633–1637CrossRefPubMed Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N, Inbal A (2002) Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 17:1633–1637CrossRefPubMed
5.
go back to reference Bick RL, Hoppensteadt D (2005) Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin App Thromb Hemost 11:1–13CrossRef Bick RL, Hoppensteadt D (2005) Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin App Thromb Hemost 11:1–13CrossRef
6.
go back to reference Foka ZJ, Lambropoulos AF, Saravelos H et al (2000) Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 15:458–462CrossRefPubMed Foka ZJ, Lambropoulos AF, Saravelos H et al (2000) Factor V Leiden and prothrombin G20210A mutations, but not methylenetetrahydrofolate reductase C677T, are associated with recurrent miscarriages. Hum Reprod 15:458–462CrossRefPubMed
7.
go back to reference den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759–762CrossRef den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759–762CrossRef
8.
go back to reference Tassies D, Espinosa G, Munoz-Rodriguez FJ et al (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43:2349–2358CrossRefPubMed Tassies D, Espinosa G, Munoz-Rodriguez FJ et al (2000) The 4G/5G polymorphism of the type 1 plasminogen activator inhibitor gene and thrombosis in patients with antiphospholipid syndrome. Arthritis Rheum 43:2349–2358CrossRefPubMed
9.
go back to reference Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79:975–979PubMed Stegnar M, Uhrin P, Peternel P et al (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79:975–979PubMed
10.
go back to reference Sheehan HL (1937) Postpartum necrosis of the anterior pituitary. J Path Bacteriol 45:189–214CrossRef Sheehan HL (1937) Postpartum necrosis of the anterior pituitary. J Path Bacteriol 45:189–214CrossRef
11.
go back to reference Veldhuis JD, Hammond JM (1980) Endocrine function after spontaneous infarction of the human pituitary: report, review, and reappraisal. Endocr Rev 1(1):100–107CrossRefPubMed Veldhuis JD, Hammond JM (1980) Endocrine function after spontaneous infarction of the human pituitary: report, review, and reappraisal. Endocr Rev 1(1):100–107CrossRefPubMed
12.
go back to reference Di Ziegra D, Kletzky DA, Mishell DR (1978) Diagnosis of Sheehan’s syndrome using sequental pituitary stimulation tests. Am J Obstet Gynecol 132:348–353CrossRef Di Ziegra D, Kletzky DA, Mishell DR (1978) Diagnosis of Sheehan’s syndrome using sequental pituitary stimulation tests. Am J Obstet Gynecol 132:348–353CrossRef
13.
go back to reference Roberts DM (1998) Sheehan’s syndrome. Am Fam Physician 244:261–266 Roberts DM (1998) Sheehan’s syndrome. Am Fam Physician 244:261–266
14.
go back to reference Gupta D, Gaiha M, Mahajan R, Daga MK (2001) Atypical presentation of sheehan’s syndrome without postpartum hemorrhage. J Assoc Physicians India 49:386–387PubMed Gupta D, Gaiha M, Mahajan R, Daga MK (2001) Atypical presentation of sheehan’s syndrome without postpartum hemorrhage. J Assoc Physicians India 49:386–387PubMed
16.
go back to reference Kalkanli S, Ayyildiz O, Tiftik N, Batun S, Isikdogan A et al (2006) Factor V Leiden mutation in venous thrombosis in southeast Turkey. Angiology 57(2):193–196CrossRefPubMed Kalkanli S, Ayyildiz O, Tiftik N, Batun S, Isikdogan A et al (2006) Factor V Leiden mutation in venous thrombosis in southeast Turkey. Angiology 57(2):193–196CrossRefPubMed
17.
go back to reference Gurgey A, Mesci L (1997) The prevalence of factor V Leiden (1691G → A) mutation in Turkey. Turk J Pediatr 39:313–315PubMed Gurgey A, Mesci L (1997) The prevalence of factor V Leiden (1691G → A) mutation in Turkey. Turk J Pediatr 39:313–315PubMed
18.
go back to reference Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M et al (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706–708PubMed Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M et al (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706–708PubMed
19.
go back to reference Ayyildiz O, Kalkanli S, Batun S, Aybak M, Isikdogan A, Tiftik N, Bolaman Z, Soker M, Muftuoglu E (2004) Prothrombin G20210A gene mutation with Lightcycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. Heart Vessels 19:164–166CrossRefPubMed Ayyildiz O, Kalkanli S, Batun S, Aybak M, Isikdogan A, Tiftik N, Bolaman Z, Soker M, Muftuoglu E (2004) Prothrombin G20210A gene mutation with Lightcycler polymerase chain reaction in venous thrombosis and healthy population in the southeast of Turkey. Heart Vessels 19:164–166CrossRefPubMed
20.
go back to reference Akar N, Misirlioglu M, Akar E, Avci F, Yalcin A (1998) Prothrombin gene 20210 G-A mutations in Turkish population. Am J Hematol 58:249CrossRefPubMed Akar N, Misirlioglu M, Akar E, Avci F, Yalcin A (1998) Prothrombin gene 20210 G-A mutations in Turkish population. Am J Hematol 58:249CrossRefPubMed
21.
go back to reference Castoldi E, Rosing J (2004) Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 11(3):176–181CrossRefPubMed Castoldi E, Rosing J (2004) Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 11(3):176–181CrossRefPubMed
22.
go back to reference Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593–1596CrossRefPubMed Bloemenkamp KW, Rosendaal FR, Helmerhorst FM et al (1995) Enhancement by factor V Leiden mutation of risk of deep vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346:1593–1596CrossRefPubMed
23.
go back to reference Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700–4702 Rosendaal FR, Koster T, Vandenbroucke JP et al (1995) High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 86:4700–4702
24.
go back to reference Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed Poort SR, Rosendaal FR, Reitsma PH, Bertina RM (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698–3703PubMed
25.
26.
go back to reference Quere I, Perneger T, Zittoun J, Bellet H, Gris JC, Daures JP et al (2002) Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 359:747–752CrossRefPubMed Quere I, Perneger T, Zittoun J, Bellet H, Gris JC, Daures JP et al (2002) Red blood cell methylfolate and plasma homocysteine as risk factors for venous thromboembolism: a matched case-control study. Lancet 359:747–752CrossRefPubMed
27.
go back to reference Hainaut P, Jaumotte J, Verhelst D, Wallemacq P, Gala JP, Lavenne E et al (2002) Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 106(2):121–125CrossRefPubMed Hainaut P, Jaumotte J, Verhelst D, Wallemacq P, Gala JP, Lavenne E et al (2002) Hyperhomocysteinemia and venous thromboembolism: a risk factor more prevalent in the elderly and in idiopathic cases. Thromb Res 106(2):121–125CrossRefPubMed
28.
go back to reference Eichinger S, Stumpflen A, Hirschi M, Bialonczyk C, Herkner K, Stain M et al (1998) Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80(4):566–569PubMed Eichinger S, Stumpflen A, Hirschi M, Bialonczyk C, Herkner K, Stain M et al (1998) Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 80(4):566–569PubMed
29.
go back to reference van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural ltube defects? Am J Hum Genet 62:1044–1051CrossRefPubMedPubMedCentral van der Put NM, Gabreels F, Stevens EM et al (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural ltube defects? Am J Hum Genet 62:1044–1051CrossRefPubMedPubMedCentral
30.
go back to reference Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169–172CrossRefPubMed Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64:169–172CrossRefPubMed
31.
go back to reference den Heijer M, Lewington S, Clarke R (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. Thromb Haemost 3:292–299CrossRef den Heijer M, Lewington S, Clarke R (2005) Homocysteine, MTHFR and risk of venous thrombosis: a meta-analysis of published epidemiological studies. Thromb Haemost 3:292–299CrossRef
32.
go back to reference Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081–1086CrossRefPubMed Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M et al (2003) Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem 49(7):1081–1086CrossRefPubMed
33.
go back to reference Segui R, Estelles A, Mira Y et al (2000) PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122–128CrossRefPubMed Segui R, Estelles A, Mira Y et al (2000) PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. Br J Haematol 111(1):122–128CrossRefPubMed
Metadata
Title
Analysis of thrombophilic genetic mutations in patients with Sheehan`s syndrome: is thrombophilia responsible for the pathogenesis of Sheehan`s syndrome?
Authors
Deniz Gokalp
Alpaslan Tuzcu
Mithat Bahceci
Orhan Ayyildiz
Murat Yurt
Yusuf Celik
Gulistan Alpagat
Publication date
01-06-2011
Publisher
Springer US
Published in
Pituitary / Issue 2/2011
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-010-0276-x

Other articles of this Issue 2/2011

Pituitary 2/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.